For the quarter ending 2026-03-31, CLNN had $750K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -8,091 | -9,226 | -8,777 | -8,170 |
| Depreciation | 355 | 360 | 365 | 770 |
| Non-cash lease expense | 157 | 153 | 148 | 270 |
| Issuance costs for common stock warrant liabilities | 393 | 0 | - | - |
| Non-cash interest income on marketable securities | - | 0 | 0 | 0 |
| Loss on initial issuance of equity | -4,582 | 0 | - | - |
| Issuance of common stock as payment of outstanding indebtedness | - | 0 | 0 | -8 |
| Change in fair value of common stock warrant liabilities | 1,060 | 789 | 1,728 | -1,995 |
| Change in fair value of derivative liabilities | 713 | -274 | -797 | 708 |
| Change in fair value of clene nanomedicine contingent earn-out liability | - | 0 | 0 | 0 |
| Change in fair value of initial stockholders contingent earn-out liability | - | 0 | 0 | 0 |
| Stock-based compensation expense | 1,312 | 1,365 | 1,703 | 3,314 |
| Loss on extinguishment of notes payable | - | 0 | - | - |
| Loss on disposal of property and equipment | - | 0 | - | - |
| Accretion of debt discount | 303 | 287 | 252 | 488 |
| Non-cash interest expense on notes payable | -378 | -372 | -216 | -24 |
| Accounts receivable | 0 | 0 | 0 | -64 |
| Inventory | 17 | -24 | -18 | 11 |
| Prepaid expenses and other current assets | 3,279 | -936 | 66 | 751 |
| Accounts payable | 417 | -477 | 541 | -412 |
| Accrued liabilities | -1,170 | 553 | -465 | -2,307 |
| Operating lease obligations | -215 | -209 | -452 | -339 |
| Net cash used in operating activities | -4,528 | -4,799 | -3,992 | -9,755 |
| Purchases of marketable securities | - | 0 | 0 | 0 |
| Proceeds from maturities of marketable securities | - | 0 | 0 | 0 |
| Purchases of property and equipment | - | 28 | 11 | 0 |
| Net cash provided by (used in) investing activities | 0 | -28 | -11 | 0 |
| Proceeds from exercise of stock options | - | 0 | 0 | 0 |
| Proceeds from issuance of common stock, net of offering costs | - | - | 3,266 | 4,977 |
| Proceeds from share subscriptions payable | - | - | 0 | - |
| Proceeds from issuance of common stock and warrants, net of offering costs | 5,324 | 10,402 | - | - |
| Proceeds from the issuance of debt and derivative liabilities | - | 0 | 1,500 | - |
| Payments of notes payable | 90 | 89 | 124 | 171 |
| Payments of finance lease obligations | - | 0 | 0 | 0 |
| Net cash provided by financing activities | 5,234 | 2,070 | 4,642 | 4,806 |
| Effect of foreign exchange rate changes on cash and restricted cash | 44 | 21 | 1 | 79 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 750 | -2,736 | 640 | -4,870 |
| Cash, cash equivalents and restricted cash beginning of period | 5,247 | 7,983 | 12,213 | - |
| Cash, cash equivalents and restricted cash end of period | 5,997 | 5,247 | 7,983 | - |
Clene Inc. (CLNN)
Clene Inc. (CLNN)